13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02466074 (ClinicalTrials.gov) | August 17, 2016 | 3/6/2015 | Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis | Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis | Multiple Sclerosis | Drug: Acetazolamide;Drug: Placebo | The University of Texas Health Science Center, Houston | NULL | Active, not recruiting | 18 Years | 55 Years | All | 60 | Phase 2 | United States |